PE20141818A1 - Sistema para la administracion de farmacos - Google Patents

Sistema para la administracion de farmacos

Info

Publication number
PE20141818A1
PE20141818A1 PE2014001141A PE2014001141A PE20141818A1 PE 20141818 A1 PE20141818 A1 PE 20141818A1 PE 2014001141 A PE2014001141 A PE 2014001141A PE 2014001141 A PE2014001141 A PE 2014001141A PE 20141818 A1 PE20141818 A1 PE 20141818A1
Authority
PE
Peru
Prior art keywords
administration
drugs
membrane
core
silica
Prior art date
Application number
PE2014001141A
Other languages
English (en)
Spanish (es)
Inventor
Heikki Lyytikainen
Harri Jukarainen
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141818(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of PE20141818A1 publication Critical patent/PE20141818A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)
PE2014001141A 2012-01-23 2013-01-22 Sistema para la administracion de farmacos PE20141818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20125069 2012-01-23

Publications (1)

Publication Number Publication Date
PE20141818A1 true PE20141818A1 (es) 2014-12-18

Family

ID=47666152

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001141A PE20141818A1 (es) 2012-01-23 2013-01-22 Sistema para la administracion de farmacos

Country Status (38)

Country Link
US (1) US10500381B2 (https=)
EP (1) EP2806893B1 (https=)
JP (1) JP6236401B2 (https=)
KR (1) KR102004014B1 (https=)
CN (1) CN104144702B (https=)
AR (1) AR089765A1 (https=)
AU (1) AU2013213514B2 (https=)
BR (1) BR112014017834B1 (https=)
CA (1) CA2861947A1 (https=)
CL (1) CL2014001935A1 (https=)
CO (1) CO7020911A2 (https=)
CR (1) CR20140358A (https=)
CU (1) CU24431B1 (https=)
CY (1) CY1120773T1 (https=)
DK (1) DK2806893T3 (https=)
DO (1) DOP2014000171A (https=)
EA (1) EA032208B1 (https=)
EC (1) ECSP14010605A (https=)
ES (1) ES2691635T3 (https=)
HR (1) HRP20181707T1 (https=)
IL (1) IL233599B (https=)
LT (1) LT2806893T (https=)
MX (1) MX355961B (https=)
MY (1) MY172812A (https=)
NZ (1) NZ627461A (https=)
PE (1) PE20141818A1 (https=)
PH (1) PH12014501654A1 (https=)
PL (1) PL2806893T3 (https=)
PT (1) PT2806893T (https=)
RS (1) RS57911B1 (https=)
SG (1) SG11201404032SA (https=)
SI (1) SI2806893T1 (https=)
TR (1) TR201815247T4 (https=)
TW (1) TWI626951B (https=)
UA (1) UA116197C2 (https=)
UY (1) UY34583A (https=)
WO (1) WO2013110856A1 (https=)
ZA (1) ZA201406206B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
US9820994B2 (en) * 2014-06-28 2017-11-21 Laboratorios Andromaco S.A. Cerclage pessary containing progesterone of prolonged, sustained, and continuous release useful for prevention of preterm birth
JP2019504021A (ja) * 2015-12-21 2019-02-14 バイエル・オーイュー 膣リングを製造する方法
WO2018202574A1 (en) 2017-05-04 2018-11-08 Bayer Oy Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception
MX2020007323A (es) * 2017-09-27 2020-09-07 Bayer Oy Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica.
CN109954198B (zh) * 2017-12-25 2021-10-12 先健科技(深圳)有限公司 药物球囊及其制备方法
CN113677326A (zh) * 2019-02-19 2021-11-19 粒子科学公司 隔室化药物递送装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303306B1 (en) * 1987-08-08 1993-03-10 Akzo N.V. Contraceptive implant
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
WO2001085132A1 (en) 2000-05-10 2001-11-15 Leiras Oy Drug delivery device, especially for the delivery of levonorgestrel
WO2002032433A1 (en) * 2000-10-20 2002-04-25 Leiras Oy Drug delivery system
AU2002313517B2 (en) * 2001-08-31 2007-09-06 Bayer Schering Pharma Oy Drug delivery system
DE10209979A1 (de) 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
DK1629844T4 (da) 2004-07-13 2012-05-29 Bayer Schering Pharma Oy Retarderet indgivelsessystem med kontrolleret initialudbrud
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP1833469A2 (en) 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US8137327B2 (en) 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
NZ577014A (en) 2006-11-20 2011-07-29 Organon Nv Helically-shaped drug delivery system
TW200930343A (en) * 2007-09-21 2009-07-16 Organon Nv Drug delivery system
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
FI121000B (fi) 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
EP2658524A1 (en) * 2010-12-27 2013-11-06 Dow Corning Corporation Drug delivery dispersion and film formed therefrom

Also Published As

Publication number Publication date
ZA201406206B (en) 2019-06-26
RS57911B1 (sr) 2019-01-31
CU24431B1 (es) 2019-07-04
HK1203802A1 (en) 2015-11-06
PH12014501654B1 (en) 2014-10-13
PL2806893T3 (pl) 2019-01-31
LT2806893T (lt) 2018-12-10
AR089765A1 (es) 2014-09-17
EA032208B1 (ru) 2019-04-30
CY1120773T1 (el) 2019-12-11
NZ627461A (en) 2016-07-29
TW201343204A (zh) 2013-11-01
TWI626951B (zh) 2018-06-21
KR20140127262A (ko) 2014-11-03
WO2013110856A1 (en) 2013-08-01
DK2806893T3 (en) 2018-11-05
US10500381B2 (en) 2019-12-10
US20140350488A1 (en) 2014-11-27
BR112014017834B1 (pt) 2021-05-18
CU20140094A7 (es) 2014-11-27
PT2806893T (pt) 2018-11-09
BR112014017834A2 (https=) 2017-06-20
IL233599B (en) 2019-07-31
CO7020911A2 (es) 2014-08-11
MX2014008906A (es) 2014-08-26
ECSP14010605A (es) 2015-12-31
CA2861947A1 (en) 2013-08-01
CR20140358A (es) 2014-11-17
JP2015504083A (ja) 2015-02-05
UY34583A (es) 2013-09-02
MX355961B (es) 2018-05-07
MY172812A (en) 2019-12-12
SI2806893T1 (sl) 2019-02-28
HRP20181707T1 (hr) 2019-02-22
AU2013213514A1 (en) 2014-08-07
CN104144702B (zh) 2018-03-06
JP6236401B2 (ja) 2017-11-22
ES2691635T3 (es) 2018-11-28
EP2806893A1 (en) 2014-12-03
AU2013213514B2 (en) 2017-07-13
UA116197C2 (uk) 2018-02-26
BR112014017834A8 (pt) 2017-07-11
SG11201404032SA (en) 2014-08-28
IL233599A0 (en) 2014-08-31
DOP2014000171A (es) 2014-08-15
CL2014001935A1 (es) 2015-04-10
EA201400834A1 (ru) 2014-12-30
TR201815247T4 (tr) 2018-11-21
CN104144702A (zh) 2014-11-12
EP2806893B1 (en) 2018-07-18
KR102004014B1 (ko) 2019-07-25
PH12014501654A1 (en) 2014-10-13

Similar Documents

Publication Publication Date Title
PE20141818A1 (es) Sistema para la administracion de farmacos
MX2014012374A (es) Compuestos organicos.
NI201400142A (es) Formas cristalinas de un modulador del receptor de androgenos
CU20170154A7 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CL2012001397A1 (es) Compuestos hetero-triciclicos condensados, moduladores de quinasa jak; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la prepararcion de medicamentos utiles en el tratamiento de enfermedades autoinmunes, cancer y trastornos del sistema nervioso central, entre otras.
CO6450625A2 (es) Sistema intrauterino para uso en tratamiento médico
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
CL2009000816A1 (es) Metodos para modificar una estructura especifica asociada a una actividad biologica; ysu uso en el tratamiento de enfermedades y sintomas como son autoinmune, oculares, snc, cancer, entre otras.
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
CL2012002570A1 (es) Compuestos derivados de ácido 2-(3heteroaril-amino-1,2,3,4-tetrahidro-9h-carbazol)-acético, composicion farnaceutica que los comprende, y su uso como medicamentos, en la profilaxis y/o el tratamiento de patologias mediadas por la modulacion de receptores de prostaglandinas d2, como trastornos alergicos o inmunitarios.
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
PE20151783A1 (es) Dispersion solida de un modulador selectivo de los receptores de progesterona
AR084695A1 (es) Nucleo medicinal con matriz porosa para dispositivo de inserto lacrimal
CU23950B1 (es) Péptidos cíclicos con actividad antineoplásica y antiangiogénica
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
MX2019004736A (es) Mini-tabletas de melatonina y metodos de fabricacion de las mismas.
AR098716A1 (es) Formas de dosificación farmacéuticas

Legal Events

Date Code Title Description
FG Grant, registration